VALUATION OF BIOTECHNOLOGY COMPANIES: REAL OPTIONS APPROACH UNDER UNCERTAINTY

Biotechnology is one of the most intensive industries in the past few decades. Essence of their operations leads to problem of determining the value of biotechnology companies, because in addition to their existing value, future product, market opportunities and intangible assets are difficult to value. Biotech companies don’t have a standard format, and simple techniques, such as financial statements analysis or discounted cash flows cannot be applied. Due to the complexity of their work and high levels of risk, alternative method such as real options is applied. The concept of financial options can be extended to the valuation of investment opportunities in commercial companies, especially in biotech. This paper explains how real options provide various perspectives on the project (investment) value in relation to situations in which the project is: delayed, expanded, abandoned, business is contracted, operations are switched, products with multiple applications are grown, and optimal date for the product launch is determined.


Variant title:
VREDNOVANJE PREDUZEĆA IZ OBLASTI BIOTEHNOLOGIJE: PRISTUP REALNIH OPCIJA U USLOVIMA NEIZVESNOSTI
Editor(s):
Cvijanovic, Drago
Issue Date:
2012-04
Publication Type:
Journal Article
DOI and Other Identifiers:
ISSN 0352-3462 (Other)
UDC 338.43:63 (Other)
CIP 33:63(497.11) (Other)
COBISS.SR-ID 27671 (Other)
PURL Identifier:
http://purl.umn.edu/123958
Published in:
Economics of Agriculture, Volume 59, Number 1
Page range:
51-62
Total Pages:
12
JEL Codes:
D04; D81; L65
Note:
Review article
Series Statement:
Economics of Agriculture 1/2012
UDC: 330.322.54:663.18




 Record created 2017-04-01, last modified 2017-05-27

Fulltext:
Download fulltext
PDF

Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)